Search research articles
Contact Us
Filters
Showing results (311-320 of 338) with videos related to
Page
of 34
Sort By:
British Heart Journal
|
May 1, 1988
Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands
F Vermeer, M L Simoons, C de Zwaan, et al.
Circulation
|
March 14, 1998
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I
K W Mahaffey, C B Granger, M A Sloan, et al.
American Heart Journal
|
September 1, 1999
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries
K W Mahaffey, C B Granger, M A Sloan, et al.
European Heart Journal
|
February 10, 2000
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT
K M Akkerhuis, J W Deckers, E Boersma, et al.
Heart (British Cardiac Society)
|
March 17, 2001
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
K M Akkerhuis, M J van Den Brand, C van Der Zwaan, et al.
Circulation
|
March 7, 1998
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators
S G Goodman, A Langer, A M Ross, et al.
International Journal of Cardiology
|
September 6, 2014
The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease
J J Brugts, Hisatomi Arima, W Remme, et al.
American Heart Journal
|
April 1, 1988
Rapid enzyme release from acutely infarcted myocardium after early thrombolytic therapy: washout or reperfusion damage?
A van der Laarse, E E van der Wall, R C van den Pol, et al.
Circulation
|
February 1, 1994
Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group
M L Simoons, M J de Boer, M J van den Brand, et al.
Cardiovascular Drugs and Therapy
|
December 17, 2008
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease
J J Brugts, M P M de Maat, E Boersma, et al.
Page
of 34
Search research articles
Search
Showing results (311-320 of 338) with videos related to
Sort By:
Page
of 34
British Heart Journal
|
May 1, 1988
Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands
F Vermeer, M L Simoons, C de Zwaan, et al.
Circulation
|
March 14, 1998
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I
K W Mahaffey, C B Granger, M A Sloan, et al.
American Heart Journal
|
September 1, 1999
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries
K W Mahaffey, C B Granger, M A Sloan, et al.
European Heart Journal
|
February 10, 2000
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT
K M Akkerhuis, J W Deckers, E Boersma, et al.
Heart (British Cardiac Society)
|
March 17, 2001
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
K M Akkerhuis, M J van Den Brand, C van Der Zwaan, et al.
Circulation
|
March 7, 1998
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators
S G Goodman, A Langer, A M Ross, et al.
International Journal of Cardiology
|
September 6, 2014
The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease
J J Brugts, Hisatomi Arima, W Remme, et al.
American Heart Journal
|
April 1, 1988
Rapid enzyme release from acutely infarcted myocardium after early thrombolytic therapy: washout or reperfusion damage?
A van der Laarse, E E van der Wall, R C van den Pol, et al.
Circulation
|
February 1, 1994
Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group
M L Simoons, M J de Boer, M J van den Brand, et al.
Cardiovascular Drugs and Therapy
|
December 17, 2008
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease
J J Brugts, M P M de Maat, E Boersma, et al.
Page
of 34